Hydroxychloroquine & Chloroquine.
It appears that the Pharmaceutical is desperate to minimise competition to their mRNA vaccines.
Hydroxychloroquine became a target after high profile endorsements for it in conjunction with Azithromycin in 2020.
When Dr. Anthony Fauci was first questioned by the press on the treatment possibility, he was clear to use the word “anecdotal” when describing a lack of evidence of effectiveness.
Fauci, an immunologist, served as the director of the National Institute of Allergy and Infectious Diseases (NIAID) since 1984. However research was undertaken under his watch (1) that showed that chloroquine has strong antiviral effects on SARS-CoV infection, which is closely genetically related to Covid-19, sharing 70% of its genome.
Both Fauci and the Media/DNC hybrid, have been doing everything to minimize and dismiss the suggestion and limit the progression of usage. Why?
In article published by the Virology Journal dated August 22, 2005, (1)
The researchers reported:
“We report, however, that chloroquine has strong antiviral effects on SARS-CoV infection of primate cells. These inhibitory effects are observed when the cells are treated with the drug either before or after exposure to the virus, suggesting both prophylactic and therapeutic advantages. In addition to the well-known functions of chloroquine, such as elevations of endosomal pH, the drug appears to interfere with terminal glycosylation of the cellular receptor, angiotensin-converting enzyme 2. This may negatively influence the virus-receptor binding and abrogate the infection, with further ramifications by the elevation of vesicular pH, resulting in the inhibition of infection and the spread of SARS CoV at clinically admissible concentrations.”
The researchers concluded :
“Chloroquine is effective in preventing the spread of SARS CoV in cell culture. Favorable inhibition of virus spread was observed when the cells were either treated with chloroquine prior to or after SARS CoV infection. In addition, the indirect immunofluorescence assay described herein represents a simple and rapid method for screening SARS-CoV antiviral compounds.“
“Chloroquine, a relatively safe, effective, and cheap drug used for treating many human diseases including malaria, amoebiosis, and human immunodeficiency virus, is effective in inhibiting the infection and spread of SARS CoV in cell culture. The fact that the drug had a significant inhibitory antiviral effect when the susceptible cells were treated either prior to or after infection suggests a possible prophylactic and therapeutic use.“
Following the French microbiologist Dr. Didier Raoult, the first trial of the combo, the NCBI released this positive review (2) on March 21, 2020. Raoult’s follow up trial with a larger sample (3) was also affirmative. In another study, Turkey claims (4) success in treating Coronavirus with broad use of malaria drug hydroxychloroquine.
Video Direct Link: https://rumble.com/embed/vat9b9/?pub=4
Hydroxychloroquine (HCQ) has shown efficacy against coronavirus disease 2019 (COVID-19) in some but not all studies. We hypothesized that a systematic review would show HCQ to be effective against COVID-19, more effective when provided earlier, not associated with worsening disease and safe.
A total of 43 reports were found that examined HCQ treatment for COVID-19 patients. Twenty-five reported positive clinical efficacy from providing HCQ to for COVID-19 patients; 15 showed no improvement with HCQ and three showed worse clinical results in patients who received HCQ.
At present, there are still numerous clinical trials ongoing around the world using HCQ/CQ in treatment of COVID-19, either alone or in combination with other therapeutics. To move forward, there are important challenges for the scientific community to conduct more work to repurpose these two ancient drugs in the combat against this deadly COVID-19 pandemic. Specifically, more mechanistic studies are necessary to fully discover the exact targets of HCQ/CQ on both SARS-CoV-2 and host cells, to clarify the potential role of autophagy and lysosome on the process of viral replication. Furthermore, more animal works are needed to reveal the pharmacokinetic characteristics of HCQ/CQ and understand the possible reason for the inconsistent effect of these two agents between in vitro and in vivo investigations. Last and most importantly, it will be critically important to conduct more clinical trials to optimize the clinical application, including potential combined therapy, to enhance the therapeutic efficacy and to reduce the adverse effects on patients. Hopefully, all the research work not only resolve the mystery regarding the therapeutic efficacy of these two drugs in COVID-19, also add more light at the end of tunnel in our fight against COVID-19.